|Bid||7.78 x 1000|
|Ask||7.79 x 800|
|Day's range||7.70 - 8.08|
|52-week range||6.26 - 13.91|
|Beta (5Y monthly)||2.79|
|PE ratio (TTM)||N/A|
|Earnings date||25 Feb 2020 - 01 Mar 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||20.67|
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present a corporate overview at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16th at 8:30 a.m. PT in San Francisco.
BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today the completion of the transfer to Pfizer of the SB-525 Hemophilia A gene therapy Investigational New Drug application (IND). Pfizer is advancing SB-525 into a Phase 3 registrational clinical study in 2020 and has already commenced enrolling patients into a Phase 3 lead-in study. Sangamo has now earned a $25 million milestone payment, per the terms of a December 2019 amendment to the parties’ collaboration agreement for the global development and commercialization of gene therapies for Hemophilia A.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, is hosting an R&D Day today beginning at 8am Eastern Time. During the event, Sangamo executives and scientists plan to provide updates across the Company’s clinical and preclinical pipeline, as well as an overview of manufacturing capabilities to support clinical and commercial supply. A live webcast link will be available on the Events and Presentations page of the Sangamo website
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the first three patients treated in the Phase 1/2 THALES study evaluating investigational ST-400 ex vivo gene-edited cell therapy in transfusion-dependent beta thalassemia (TDT). The data are featured in a poster presentation on December 9, 2019 at the 61st Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL. The ST-400 ASH poster will be available on Sangamo’s website in the Investors and Media section under Events and Presentations at the beginning of the poster session at 10am Eastern Time.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE), today announced updated follow-up results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy in patients with severe hemophilia A. The data showed that SB-525 was generally well tolerated and demonstrated sustained increased Factor VIII (FVIII) levels following treatment with SB-525 through to 44 weeks, the extent of follow-up for the longest treated patient in the 3e13 vg/kg dose cohort. Data from 11 patients treated with SB-525 will be featured in a poster presentation today, December 7, 2019, at the 61st Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL. The SB-525 ASH poster, which includes the full set of data, is available on Sangamo’s website in the Investors and Media section under Events and Presentations.
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the Company plans to host an R&D Day on December 17, 2019 at 8am Eastern Time in New York City. Sangamo executives and scientists will provide updates across the Company’s clinical and preclinical pipeline of genomic medicine product candidates, offer perspective on clinical data being presented at the upcoming American Society of Hematology Annual Meeting, and provide an overview of the Company’s manufacturing capabilities to support clinical and commercial supply.
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, today announced the appointment of James R. Meyers, an accomplished pharmaceutical executive with three decades of commercial experience, to the Company's Board of Directors. "We are pleased that Jim has joined the Sangamo Board of Directors," said Sandy Macrae, Chief Executive Officer of Sangamo. Mr. Meyers has over 30 years of commercial leadership experience in the biotechnology industry and worked at Gilead from 1996 until his retirement in February 2018.
BioMarin (BMRN) submits an MAA in Europe for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today that the United Kingdom’s (UK) Medicines Healthcare Products Regulatory Agency (MHRA) has granted authorization of the first-in-human clinical trial to evaluate a Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) therapy. TX200 is being studied for the prevention of immune-mediated rejection following HLA-A2 mismatched kidney transplantation for end-stage renal disease (ESRD). Sangamo expects to open the first clinical sites for the STEADFAST study in 2020.
Sangamo Therapeutics, Inc. , a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m.
Sangamo (SGMO) delivered earnings and revenue surprises of 27.27% and 56.70%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will be featured in poster presentations at the 61st Annual Meeting of the American Society of Hematology (ASH). The SB-525 poster will show updated Alta study data including durability of Factor VIII (FVIII) levels, bleeding rate, factor usage, and safety, for all five patients in the high dose cohort of 3e13 vg/kg, with approximately 4 months to 11 months of follow-up after treatment with SB-525.
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today the appointment of Sung Lee as Executive Vice President and Chief Financial Officer, effective October 31, 2019. Mr. Lee oversees finance, facilities and information technology functions for Sangamo and reports to the Chief Executive Officer. “I am excited to welcome Sung to the leadership team and believe that his exceptional track record of improving operational performance, leading large teams, and communicating with investors, as well as his deep experience and success in financial planning and analysis, will have a significant impact on Sangamo as we continue to grow,” said Sandy Macrae, Sangamo's Chief Executive Officer.
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.
If you want to know who really controls Sangamo Therapeutics, Inc. (NASDAQ:SGMO), then you'll have to look at the...
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today the appointment of Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer. Dr. Cockroft will oversee all clinical development activities and operations and will report to the Executive Vice President of Research and Development. “Bettina brings over 20 years of clinical development experience, having worked across multiple therapeutic areas and leading programs in several countries,” said Adrian Woolfson, BM., B.Ch., Ph.D., Executive Vice President, Research and Development.